Format

Send to

Choose Destination
Oncology. 1988;45(5):344-5.

Phase II evaluation of Ly156758 in metastatic breast cancer.

Author information

1
Department of Medical Oncology, University of Texas M.D. Anderson Hospital and Tumor Institute, Houston.

Abstract

Fourteen patients with disseminated breast cancer with primary or secondary resistance to tamoxifen were treated with LY156758. There were no complete or partial responses and 1 patient showed a minor response. These data illustrate that LY156758 did not have significant antitumor activity in patients previously treated with tamoxifen therapy.

PMID:
3412740
DOI:
10.1159/000226637
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center